Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Jan 28, 2011

Premium

Integrated Diagnostics announced this week that it has appointed Kenneth Fang chief medical officer and vice president of translational research and clinical development. He will lead the company's efforts for early detection of diseases including lung cancer and Alzheimer's.

Previously Fang was senior director for clinical development at XDx and a faculty member at the University of California at San Francisco. He also co-founded Modus BioMedicine.


Proteome Sciences announced that Alf Lindberg has resigned from its board of directors.


Catherine Derasp this month joined PharmaNet as vice president of clinical operations for the company's Phase I trials, overseeing management of its 350-bed clinical operations in Montreal and Quebec City, Canada.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.